VALSECCHI MARIA GRAZIA

Conter, V., Valsecchi, M., Cario, G., Zimmermann, M., Attarbaschi, A., Stary, J., et al. (2024). Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. JOURNAL OF CLINICAL ONCOLOGY, 42(8), 915-926 [10.1200/JCO.23.01388]. Detail

Bugarin, C., Antolini, L., Buracchi, C., Matarraz, S., Coliva, T., Van der Velden, V., et al. (2024). Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia. HAEMATOLOGICA, 109(2 (February, 2024)), 521-532 [10.3324/haematol.2023.282805]. Detail

Taurino, G., Dander, E., Chiu, M., Pozzi, G., Maccari, C., Starace, R., et al. (2024). Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP‐ALL cell survival and a potential therapeutic target. BRITISH JOURNAL OF HAEMATOLOGY, 205(1 (July 2024)), 175-188 [10.1111/bjh.19516]. Detail

Soria, A., Graziano, F., Ghilardi, G., Lapadula, G., Gasperina, D., Benatti, S., et al. (2024). Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort. HELIYON, 10(16) [10.1016/j.heliyon.2024.e36102]. Detail

Risca, G., Zheng, H., Valsecchi, M., Galimberti, S. (2024). Basket trials in very rare diseases: are they feasible?. Intervento presentato a: International Society for Clinical Biostatistics (ISCB), Salonicco, Grecia. Detail